Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody developed to treat a variety of solid cancer types. In June, 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.